Atrial Fibrillation and Ischemic Stroke: A Clinical Review

Area of Science:

• Cardiology
• Neurology
• Thrombosis

Background:

• Atrial fibrillation (AF) is a major risk factor for ischemic stroke, increasing stroke risk fivefold and mortality twofold.
• The concept of atrial cardiopathy provides a framework for understanding AF and thromboembolism as interconnected pathological processes.
• Screening asymptomatic patients for AF has not shown improved clinical outcomes, but monitoring is crucial for detecting silent or paroxysmal AF in embolic stroke of undetermined source.

Purpose of the Study:

• To review current understanding and management strategies for stroke in patients with atrial fibrillation.
• To discuss evolving treatment options for stroke prevention in AF.
• To highlight ongoing research into optimal anticoagulation timing after acute ischemic stroke in AF patients.

Main Methods:

• Review of current literature on atrial fibrillation, stroke mechanisms, and prevention strategies.
• Analysis of evidence supporting different anticoagulation therapies and interventions.
• Discussion of clinical trial data and emerging treatment guidelines.

Main Results:

• Direct oral anticoagulants are effective and safe alternatives to warfarin for stroke prevention in AF.
• Left atrial appendage exclusion is a viable option for patients unable to tolerate anticoagulation.
• Optimal timing for initiating or resuming anticoagulation after acute ischemic stroke in AF patients is under active investigation.

Conclusions:

• Atrial fibrillation poses a significant stroke risk, necessitating effective prevention strategies.
• Management involves risk stratification (CHA2DS2-VASc score), anticoagulation, or left atrial appendage exclusion.
• Further research is needed to establish optimal anticoagulation timing post-stroke to balance efficacy and safety.